Journal of Drug Targeting最新文献_第9页

A pioneer review on lactoferrin as versatile macromolecular ligand for targeting cancer: recent advances. 乳铁蛋白作为靶向癌症的多功能大分子配体的研究进展

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-07-14 DOI: 10.1080/1061186X.2025.2529528

Nidhi Sharma, Nousheen Khatoon, Mohammad Adnan Raza, Suprit Dilip Saoji, Dilpreet Singh

{"title":"A pioneer review on lactoferrin as versatile macromolecular ligand for targeting cancer: recent advances.","authors":"Nidhi Sharma, Nousheen Khatoon, Mohammad Adnan Raza, Suprit Dilip Saoji, Dilpreet Singh","doi":"10.1080/1061186X.2025.2529528","DOIUrl":"10.1080/1061186X.2025.2529528","url":null,"abstract":"This review critically evaluates the emerging role of lactoferrin, an iron-chelating glycoprotein, as a macromolecular ligand in precision cancer therapy. Lactoferrin exhibits potent anti-tumour, anti-inflammatory, and immunomodulatory properties and targets cancer cells via high-affinity binding to transferrin and LDL receptor-related proteins, enhancing selectivity and minimizing off-target toxicity. It modulates key oncogenic pathways such as PI3K/Akt and MAPK to suppress tumour growth and metastasis. Nanoformulations-like liposomes and polymeric nanoparticles-improve pharmacokinetics, enable targeted drug delivery, and enhance therapeutic efficacy. Lactoferrin's ability to cross biological barriers, including the blood-brain barrier via receptor-mediated transcytosis, offers promise for treating difficult cancers such as glioblastoma. Additionally, it enhances anti-tumour immunity by activating NK cells and polarizing macrophages to the M1 phenotype. Importantly, lactoferrin helps overcome multidrug resistance by modulating efflux pumps like P-glycoprotein. Integrating molecular insights with preclinical and clinical evidence, this review underscores lactoferrin's transformative potential in precision oncology through advanced nanoformulations and synergistic immunomodulatory mechanisms.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-19"},"PeriodicalIF":4.3,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Golgi Apparatus as a Strategic Target in Cancer: Mechanisms, Diagnosis and Therapeutic Opportunities. 高尔基体作为癌症的战略靶点：机制、诊断和治疗机会。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-07-14 DOI: 10.1080/1061186X.2025.2527867

Chao Cui, Chenglu Sun, Peng Yuan, Shibo Tian, Hailong Xie, Funeng Xu, Haohuan Li

引用次数: 0

Employing covalent organic framework (COF) as carrier in an aptamer-targeted theranostic nanoplatform: investigation of its therapeutic and diagnostic properties in vitro and in vivo. 采用共价有机框架（COF）作为载体的适体靶向治疗纳米平台：其体外和体内治疗和诊断特性的研究。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-07-09 DOI: 10.1080/1061186X.2025.2527865

Seyed Mojtaba Mashmoul Moghadam, Mohammad Ramezani, Mona Alibolandi, Khalil Abnous, Seyed Mohammad Taghdisi

引用次数: 0

Off-target effects of the NADPH oxidase inhibitor mitoapocynin-encapsulated nanoparticles and free-drug oral treatment in a rat DFP model of neurotoxicity. NADPH氧化酶抑制剂mitoapocynin包封纳米颗粒对大鼠DFP神经毒性模型的脱靶效应和口服游离药物治疗。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-07-08 DOI: 10.1080/1061186X.2025.2523995

Christina Meyer, Claire Holtkamp, Tyler Harm, Elizabeth Grego, Lucas Showman, Nikhil S Rao, Suraj S Vasanthi, Nyzil Massey, Balaji Narasimhan, Thimmasettappa Thippeswamy

{"title":"Off-target effects of the NADPH oxidase inhibitor mitoapocynin-encapsulated nanoparticles and free-drug oral treatment in a rat DFP model of neurotoxicity.","authors":"Christina Meyer, Claire Holtkamp, Tyler Harm, Elizabeth Grego, Lucas Showman, Nikhil S Rao, Suraj S Vasanthi, Nyzil Massey, Balaji Narasimhan, Thimmasettappa Thippeswamy","doi":"10.1080/1061186X.2025.2523995","DOIUrl":"10.1080/1061186X.2025.2523995","url":null,"abstract":"Acute exposure to diisopropylfluorophosphate (DFP), an organophosphate (OP), produces chronic neurological effects such as spontaneous seizures and behavioural comorbidities. Achieving optimal drug bioavailability in the brain by conventional routes to treat OP-induced neurotoxicity is challenging. Therefore, we investigated polyanhydride nanoparticles (NPs)-mediated drug delivery via the intramuscular route in rats for improved bioavailability of an antioxidant, NADPH oxidase inhibitor mitoapocynin (MPO). We evaluated the tolerability of blank NPs (4 mg, i.m.), MPO-encapsulated NPs (MPO-NP, 4 mg, i.m., single dose) and free MPO-oral (60 mg/kg, daily for three days) after exposure to DFP. Bodyweight, serum biochemistry, and kidney, lung and liver histology revealed no adverse responses to blank NPs. Markers of oxidative stress, neuronal loss and astrocyte reactivity were also no different from control. In DFP-exposed animals treated with MPO-NP and MPO-oral, there was significant weight loss, abnormal liver and kidney parameters, and elevated GP91phox and astrocytes in the brain. Our findings demonstrate that NP delivery via the intramuscular route is safe. DFP and MPO induced off-target effects, but not DFP or MPO treatment alone, which highlights the complexity of dosing regimens in OP models. Intranasal MPO-NP delivery and dose optimisation in the DFP model are required to determine the efficacy of MPO in future studies.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-11"},"PeriodicalIF":3.9,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12354291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polymyxin B delivery systems: smart solutions for improved antibacterial activity and reduced toxicity. 多粘菌素B输送系统：提高抗菌活性和降低毒性的智能解决方案。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-07-08 DOI: 10.1080/1061186X.2025.2527859

Ying Cheng, Mingdong Yang, Bin Lin, Wei Hu, Yangmin Hu, Haibin Dai, Junjun Xu

引用次数: 0

Emerging trends in polymeric mucoadhesive nanocarriers: a promising option for intravaginal HIV preexposure prophylaxis. 新兴的高分子黏附纳米载体：阴道内HIV暴露前预防的一个有希望的选择。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-07-02 DOI: 10.1080/1061186X.2025.2523991

Avichal Kumar, Dhruti Avlani, S Narasimha Murthy, H N Shivakumar, Shammy Jindal

{"title":"Emerging trends in polymeric mucoadhesive nanocarriers: a promising option for intravaginal HIV preexposure prophylaxis.","authors":"Avichal Kumar, Dhruti Avlani, S Narasimha Murthy, H N Shivakumar, Shammy Jindal","doi":"10.1080/1061186X.2025.2523991","DOIUrl":"10.1080/1061186X.2025.2523991","url":null,"abstract":"The emergence of novel long-acting and antiretroviral (ARV) drug delivery systems has reshaped the landscape of HIV pre-exposure prophylaxis (PrEP). Intravaginal delivery platforms are increasingly recognised for their ability to deliver ARVs directly at the portal of viral entry. These systems are well retained at the portal, ensuring sustained local inhibitory levels, minimising systemic exposure. Compared to oral PrEP, these systems offer better protection against viral transmission, reduce dosing frequency and minimise systemic side effects. Among these systems, polymeric nanoparticles (NPs) stand out due to their customisable surface chemistry, mucoadhesive potential and sustained drug release profiles, ensuring enhanced mucosal retention and minimal systemic absorption. Recent innovations integrate these NPs into versatile platforms such as in situ gelling systems, bioadhesive films, microneedles, vaginal rings and electrospun nanofibres. These specialised platforms have demonstrated superior user acceptance, stability and pharmacokinetics compared to traditional vaginal formulations. Cell-based HIV challenge models using engineered TZM-bl and PHA-stimulated peripheral blood mononuclear cells (PBMCs) have emerged as reliable in silico tools for evaluation of viral inhibition, cytotoxicity and mucosal interaction of NPs. This review critically highlights recent advances in intravaginal polymeric NP-based carrier systems for effective and sustained HIV prevention.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-25"},"PeriodicalIF":4.3,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144497189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sacituzumab govitecan in HER2-negative breast cancer: redefining treatment paradigms. Sacituzumab Govitecan治疗her2阴性乳腺癌：重新定义治疗范式

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-07-02 DOI: 10.1080/1061186X.2025.2525372

Avinash Khadela, Kashvy R Morakhia, Nishra H Shah, Vibha G Kanjani, Vraj B Shah, Hetvi B Bharadia, Rushabh Kothari, Manthan Merja

{"title":"Sacituzumab govitecan in HER2-negative breast cancer: redefining treatment paradigms.","authors":"Avinash Khadela, Kashvy R Morakhia, Nishra H Shah, Vibha G Kanjani, Vraj B Shah, Hetvi B Bharadia, Rushabh Kothari, Manthan Merja","doi":"10.1080/1061186X.2025.2525372","DOIUrl":"10.1080/1061186X.2025.2525372","url":null,"abstract":"Human epidermal growth factor 2-negative breast cancer (HER2-BC) is characterised by the lack of HER2 amplification and encompasses triple-negative breast cancer and hormone receptor-positive HER2-negative breast cancer. Triple-negative breast cancer is distinguished by a total lack of oestrogen and progesterone receptors, along with the lack of HER2 amplification. While hormone receptor-positive HER2-negative breast cancer is marked by expression of oestrogen receptors with or without progesterone receptors. The major drawback of triple-negative breast cancer is the lack of an enforceable biomarker, and that of hormone receptor-positive HER2-negative breast cancer is endocrine therapy resistance. Consequently, these therapeutic failures result in relapse/recurrence, disease progression, and ultimately a poor prognosis. Sacituzumab govitecan is a novel 3rd generation antibody-drug conjugate that selectively blocks trophoblast cell-surface antigen-2, a highly expressed protein in HER2-BC. This review elaborates on the shortcomings of the standard therapeutic regimens in HER2-BC and the role of Sacituzumab govitecan in addressing these limitations. Clinical trials proposing its application in locally advanced HER2-BC have also been included. Furthermore, clinical trials showcasing the combination of Sacituzumab govitecan with numerous therapeutic modalities improving patient survival and quality of life in metastatic disease have also been included in the text.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-14"},"PeriodicalIF":4.3,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144497190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Protective efficacy of pDNA vaccine candidate against SARS-CoV-2 in Syrian golden hamsters. pDNA候选疫苗对叙利亚金仓鼠SARS-CoV-2的保护作用

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-07-02 DOI: 10.1080/1061186X.2025.2521811

Iman Almansour Alzamil, Serguei Golovan, Jennifer Pickens, Krista Salley, Michael Roberts

{"title":"Protective efficacy of pDNA vaccine candidate against SARS-CoV-2 in Syrian golden hamsters.","authors":"Iman Almansour Alzamil, Serguei Golovan, Jennifer Pickens, Krista Salley, Michael Roberts","doi":"10.1080/1061186X.2025.2521811","DOIUrl":"10.1080/1061186X.2025.2521811","url":null,"abstract":"Seasonal SARS-CoV-2 vaccination is known as an efficient way to control the COVID-19 pandemic. However, the currently approved mRNA and protein vaccines are thermally unstable and require further encapsulation and ultra-cold chain transportation and storage. Therefore, alternative platforms that can overcome this limitation are needed. pDNA has emerged as an attractive next-generation vaccine platform due to its high thermal stability. Here, we developed pDNA-based SARS-CoV-2 vaccine candidate and conducted a preclinical protective efficacy evaluation in Syrian golden hamsters. Administration of S.opt.FL pDNA vaccine was able to induce higher S-specific SARS-CoV-2 binding and neutralising antibody levels. Importantly, S-specific IgG2 which represented Th1-mediated immune responses was predominantly induced after pDNA vaccination. Besides, animal group receiving three doses induced higher neutralising antibody responses compared to animal group receiving two doses. In addition, we determined that the Th1-skewed immune response was important in conferring protection upon virus challenge. These results indicate that intramuscular delivery of S.opt.FL pDNA vaccine is safe and effective in preventing SARS-CoV-2 infection. The study shed new light on the importance of the IgG isotype for the development of SARS-CoV-2 vaccine candidates. Furthermore, our findings can be used to support further testing of several pDNA-based vaccine candidates against other pathogens.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-9"},"PeriodicalIF":4.3,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144333189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exogenous GABA as a natural epigenetic modifier for managing glycemic memory and diabetic nephropathy by modifying the epigenetic axis. 外源性GABA作为一种天然表观遗传修饰因子，通过修饰表观遗传轴来管理血糖记忆和糖尿病肾病。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-07-02 DOI: 10.1080/1061186X.2025.2523990

Kriti Kushwaha, Debojyoti Mandal, Sourbh Suren Garg, Rupal Dubey, Navneet Khurana, Jeena Gupta

{"title":"Exogenous GABA as a natural epigenetic modifier for managing glycemic memory and diabetic nephropathy by modifying the epigenetic axis.","authors":"Kriti Kushwaha, Debojyoti Mandal, Sourbh Suren Garg, Rupal Dubey, Navneet Khurana, Jeena Gupta","doi":"10.1080/1061186X.2025.2523990","DOIUrl":"10.1080/1061186X.2025.2523990","url":null,"abstract":"Background: Glycemic memory contributes to the progression of diabetic nephropathy (DN) despite glycemic control. This study investigates γ-aminobutyric acid (GABA), a natural compound with 82.5% structural similarity to metformin, for its potential in mitigating glycemic memory and DN.Methods: Structural similarity and molecular docking identified GABA as a SIRT1-targeting metformin analog (binding affinity: 5.8 kcal/mol), supported by ADME profiling. In vitro assays assessed antioxidant activity (DPPH IC50: 141.09 µg/mL), cytotoxicity (MTT assay), oxidative stress markers, and histone H3 acetylation. In vivo, high-fat diet-fed Sprague-Dawley rats underwent dietary reversal and GABA treatment (100/200 mg/kg) to evaluate metabolic, renal, hepatic, oxidative, and epigenetic effects.Results: GABA maintained >90% cell viability at 5 µM, with no cytotoxicity up to 150 µM. It reduced oxidative markers and restored histone acetylation in vitro. In vivo, 200 mg/kg GABA treatment significantly reduced cholesterol (44.44%), triglycerides (28.64%), and LDL (40.80%), while increasing HDL by 103.65%. At 100 mg/kg, GABA lowered blood urea (30.43%), creatinine (4.65%), uric acid (75.00%), bilirubin (53.57%), SGOT (54.24%), SGPT (39.52%), and ALP (60.58%), with histopathological improvements in renal tissues.Conclusion: GABA exhibits antioxidant, hepatoprotective, and renoprotective properties, highlighting its potential as a therapeutic agent for glycemic memory-associated DN.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-14"},"PeriodicalIF":4.3,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Local delivery of ibrutinib by folate receptor-mediated targeting PLGA-PEG nanoparticles to glioblastoma multiform: in vitro and in vivo studies. 叶酸受体介导的靶向PLGA-PEG纳米颗粒对多形性胶质母细胞瘤的局部递送伊鲁替尼：体外和体内研究

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2025-07-01 Epub Date: 2025-02-24 DOI: 10.1080/1061186X.2025.2468749

Bahar Morshedi, Mehdi Esfandyari-Manesh, Fatemeh Atyabi, Mohammad Hossein Ghahremani, Rassoul Dinarvand

{"title":"Local delivery of ibrutinib by folate receptor-mediated targeting PLGA-PEG nanoparticles to glioblastoma multiform: in vitro and in vivo studies.","authors":"Bahar Morshedi, Mehdi Esfandyari-Manesh, Fatemeh Atyabi, Mohammad Hossein Ghahremani, Rassoul Dinarvand","doi":"10.1080/1061186X.2025.2468749","DOIUrl":"10.1080/1061186X.2025.2468749","url":null,"abstract":"Glioblastoma multiforme (GBM) is a widespread and life-threatening kind of brain cancer, which has a high mortality rate. Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, irreversibly adheres to a conserved cysteine residue of two enzymes BTK and BMX, inhibiting their kinase activities, which leads to suppression of the growth of glioma cells. This study synthesised PLGA-PEG-folate (PPF) polymer and subsequently encapsulated ibrutinib within PPF nanoparticles (IBT-PPF-NPs). H NMR spectra confirmed the synthesis of PPF polymer. The efficiency of IBT-PPF-NPs was 97 ± 2.26% with 8.8 ± 0.2% drug loading. The particle size was 208 ± 4.8 nm. The IC50 value of free ibrutinib, IB-PPF-NPs and ibrutinib encapsulated in PLGA NPs (IB-P-NPs) was 10.2, 7.6 and 10.13 µM in C6 cell lines, whereas in U-87 MG cells was 24.4, 16 and 25.2 µM, respectively. The cellular uptake of FITC-PPF-NPs increased from 47.6% to 90.3% in C6 cells and from 55% to 97.3% in U-87 MG cells compared to FITC-P-NPs. The in vivo results indicate a significant reduction in tumour size in treatment groups in comparison to control groups, while the group that received the intratumoural injection of IB-PPF-NPs exhibited a greater reduction. The folate-targeting agent enhances the nanoparticles' effectiveness by promoting their uptake through the endocytosis pathway.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1026-1041"},"PeriodicalIF":4.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0